PTD-N5-1
PTD-N5-1 is an IRF5 inhibitory peptide. PTD-N5-1 blocks the activation of IRF5. PTD-N5-1 inhibits β-glucan-induced IL-12 production in bone marrow-derived dendritic cells pre-stimulated with IFN-γ. PTD-N5-1 reduces the levels of IL-12 and IFN-γ in the kidneys of mice with Candida albicans infection. PTD-N5-1 is applicable to the research of Candida albicans infection.
For research use only. We do not sell to patients.
- CAS No.: 2088834-68-6
- Formula: C148H248N52O30S
- Molecular Weight:3267.95
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
IRF5 |
IFN-γ |
IL-12 |
In Vitro
PTD-N5-1 (N5-1) (50 μM) completely blocks β-glucan-induced IL-12p70 production in IFN-γ-primed wild-type and Clec2d-deficient mouse bone marrow-derived dendritic cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:IFN-γ-primed wild-type mouse bone marrow-derived dendritic cells (BMDCs), IFN-γ-primed Clec2d-deficient mouse bone marrow-derived dendritic cells (BMDCs)
-
Concentration:50 μM
-
Incubation Time:6 h (stimulation with curdlan plus IFN-γ; pretreatment prior to stimulation)
-
Result:Completely blocked β-glucan-induced IL-12p70 production in IFN-γ-primed wild-type BMDCs.
Completely blocked β-glucan-induced IL-12p70 production in IFN-γ-primed Clec2d-deficient BMDCs.
In Vivo
Chemical Information
-
CAS No. 2088834-68-6
-
Molecular Weight 3267.95
-
Formula C148H248N52O30S
-
Sequence
Asp-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-Pro-Arg-Arg-Val-Arg-Leu-Lys
-
Sequence Shortening
DRQIKIWFQNRRMKWKKPRRVRLK
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Monocyte-derived dendritic cell differentiation
Human monocyte-derived dendritic cells are generated by isolating PBMC-derived monocytes and culturing them with GM-CSF plus IL-4, which produces cells with dendritic-cell antigen-presenting properties, reduced monocyte phenotype, and increased dendritic-cell functional readouts such as antigen uptake, allogeneic T-cell stimulation, and expression of markers including HLA-DR, CD80, CD86, CD83, CD1a, or CD209 depending on protocol and maturation state. The main readout is phenotypic and functional differentiation: immature MoDCs are commonly evaluated by loss or reduction of CD14 with acquisition of dendritic-cell markers and antigen uptake capacity, whereas mature MoDCs are evaluated by increased CD83, CD80, CD86, HLA-DR, and T-cell stimulatory function after exposure to maturation stimuli such as TNF-α or a cytokine/PGE2 cocktail.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)